JP2019523260A - キラルペプチド - Google Patents

キラルペプチド Download PDF

Info

Publication number
JP2019523260A
JP2019523260A JP2019503646A JP2019503646A JP2019523260A JP 2019523260 A JP2019523260 A JP 2019523260A JP 2019503646 A JP2019503646 A JP 2019503646A JP 2019503646 A JP2019503646 A JP 2019503646A JP 2019523260 A JP2019523260 A JP 2019523260A
Authority
JP
Japan
Prior art keywords
amino acid
peptide agent
tetramer peptide
tetramer
orn
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP2019503646A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019523260A5 (https=
Inventor
アンドリュー ディー． レビン，
アンドリュー ディー． レビン，
Original Assignee
カーノット， エルエルシー
カーノット， エルエルシー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by カーノット， エルエルシー, カーノット， エルエルシー filed Critical カーノット， エルエルシー
Publication of JP2019523260A publication Critical patent/JP2019523260A/ja
Publication of JP2019523260A5 publication Critical patent/JP2019523260A5/ja
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1016—Tetrapeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/101—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1019—Tetrapeptides with the first amino acid being basic
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
JP2019503646A 2016-04-11 2017-04-10 キラルペプチド Ceased JP2019523260A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662321168P 2016-04-11 2016-04-11
US62/321,168 2016-04-11
PCT/US2017/026869 WO2017180535A1 (en) 2016-04-11 2017-04-10 Chiral peptides

Publications (2)

Publication Number Publication Date
JP2019523260A true JP2019523260A (ja) 2019-08-22
JP2019523260A5 JP2019523260A5 (https=) 2020-03-12

Family

ID=60042852

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019503646A Ceased JP2019523260A (ja) 2016-04-11 2017-04-10 キラルペプチド

Country Status (7)

Country Link
US (2) US10870678B2 (https=)
EP (1) EP3442990A4 (https=)
JP (1) JP2019523260A (https=)
CN (1) CN109563131A (https=)
AU (2) AU2017249218B2 (https=)
CA (1) CA3020393A1 (https=)
WO (1) WO2017180535A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3898653A4 (en) 2018-12-18 2022-08-24 Stealth BioTherapeutics Inc. ANALOGS TARGETING MITOCHONDRIAL DISEASES
US12404300B2 (en) 2018-12-18 2025-09-02 Stealth Biotherapeutics Inc. Mitochondria-targeting peptides
US12215173B2 (en) 2019-08-07 2025-02-04 HUMANWELL PHARMACEUTICAL US, Inc. Kappa opioid receptor peptide amide ligands
US20210255196A1 (en) * 2020-01-17 2021-08-19 Waters Technologies Corporation Low binding surfaces for peptide mapping
EP4114429A2 (en) * 2020-03-06 2023-01-11 Allegro Pharmaceuticals, LLC Treatments for improving or lessening impairment of mitochondrial function
KR20230024419A (ko) 2020-06-25 2023-02-20 휴먼웰 파마슈티컬 유에스 의학적 장애 치료용 펩티드
CN117881411A (zh) 2021-06-01 2024-04-12 艾迪雅生物有限责任公司 用于眼部药物的延长释放药物递送系统和使用方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012521355A (ja) * 2009-03-20 2012-09-13 ザ ジェネラル ホスピタル コーポレイション ディー ビー エイ マサチューセッツ ジェネラル ホスピタル 熱傷及び二次性合併症の予防及び治療方法
JP2013501802A (ja) * 2009-08-12 2013-01-17 コーネル ユニヴァーシティー 代謝性症候群を予防し又は治療するための方法
JP2015507611A (ja) * 2011-12-09 2015-03-12 ステルス ペプチドズ インターナショナル インコーポレイテッド 芳香族カチオン性ペプチドおよびその使用
WO2015048647A1 (en) * 2013-09-30 2015-04-02 Cornell University Cardiolipin-targeted peptides inhibit beta-amyloid oligomer toxicity

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2656854T1 (sl) 2003-02-04 2015-09-30 Cornell Research Foundation, Inc. Uporabe aromatsko-kationskega peptida
WO2008154373A1 (en) 2007-06-07 2008-12-18 Institute For Hepatitis And Virus Research 2-amino-2,7-dideoxy-alpha-d-glycero-d-gluco-heptopyranosyl inhibitors of positive sense single-stranded rna envelope viruses
CA2701274A1 (en) * 2007-10-02 2009-04-09 Mdrna, Inc. Lipopeptides for delivery of nucleic acids
DK2262520T3 (en) 2008-02-26 2017-08-07 Univ Cornell COMPOSITIONS FOR PREVENTION AND TREATMENT OF Kidney Injury
JP5238297B2 (ja) 2008-03-04 2013-07-17 シャープ株式会社 認証方法および入力装置
PL2470191T3 (pl) 2009-08-24 2014-09-30 Stealth Peptides Int Inc Sposoby i kompozycje do profilaktyki lub leczenia stanów okulistycznych
EP2485749A4 (en) 2009-10-05 2013-07-24 Univ Cornell METHOD FOR THE PREVENTION AND TREATMENT OF HEART FAILURE
EP3266462A1 (en) 2009-12-31 2018-01-10 Stealth Peptides International, Inc. Methods for performing a coronary artery bypass graft procedure
AU2011207432A1 (en) 2010-01-25 2012-08-02 Cornell University Aromatic-cationic peptides and uses of same
EP3332795A1 (en) 2010-02-26 2018-06-13 Cornell University Cornell Center For Technology, Enterprise & Commercialization ("CCTEC") Mitochondrial-targeted antioxidants protect against mechanical ventilation-induced diaphragm dysfunction and skeletal muscle atrophy
JP2013532124A (ja) 2010-05-03 2013-08-15 ステルス ペプチドズ インターナショナル インコーポレイテッド 芳香族系陽イオンペプチド及びその使用
JP6319738B2 (ja) 2010-07-09 2018-05-09 ステルス ペプチドズ インターナショナル インコーポレイテッド 虚血／再灌流障害に続くノーリフローの予防又は処置方法
CA2831151A1 (en) 2011-03-24 2012-09-27 Cornell University Aromatic-cationic peptides and uses of same
AU2012271691A1 (en) 2011-06-14 2014-01-16 Stealth Peptides International, Inc. Aromatic-cationic peptides and uses of same
AU2012315586B2 (en) 2011-09-29 2017-07-20 Mayo Foundation For Medical Education And Research Aromatic-cationic peptides and methods for using same
WO2013059071A1 (en) 2011-10-17 2013-04-25 Cornell University Aromatic-cationic peptides and uses of same
HK1204988A1 (en) 2012-02-22 2015-12-11 Stealth Peptides International, Inc. Methods and compositions for preventing or treating ophthalmic conditions
CA2865409C (en) 2012-02-23 2020-07-21 Cornell University Aromatic-cationic peptides and uses of same
JP6317324B2 (ja) 2012-03-30 2018-04-25 ステルス ペプチドズ インターナショナル インコーポレイテッド 神経障害を予防および処置するための方法および組成物
CA2870200A1 (en) 2012-04-12 2013-10-17 Stealth Peptides International, Inc. Aromatic-cationic peptides and uses of same
ES2981865T3 (es) * 2012-07-11 2024-10-10 Gemvax & Kael Co Ltd Conjugado que comprende un péptido de penetración celular y composiciones que comprenden el mismo
US20140034183A1 (en) 2012-07-31 2014-02-06 Viz Enterprises, Llc Cap assembly for dispensing a dispensable component and method of making and using the same
AU2013334788A1 (en) 2012-10-22 2015-06-04 Henry Ford Health Systems Methods for reducing risks associated with heart failure and factors associated therewith
EP2928562A4 (en) 2012-12-06 2016-06-22 Stealth Peptides Int Inc PEPTIDE THERAPEUTIC PRODUCTS AND METHODS OF USE
CN110339339A (zh) 2013-03-01 2019-10-18 康德生物医疗技术公司 治疗线粒体疾病的方法
WO2014165607A2 (en) 2013-04-02 2014-10-09 Stealth Peptides International, Inc. Aromatic-cationic peptide formulations, compositions and methods of use
CA2919992C (en) 2013-08-01 2022-08-09 Stealth Biotherapeutics Corp Methods and compositions for preventing or treating leber's hereditary optic neuropathy
WO2015023680A1 (en) 2013-08-12 2015-02-19 Stealth Peptides International, Inc. Combination therapy for the treatment of ischemia-reperfusion injury
JP6480921B2 (ja) 2013-09-27 2019-03-13 コーネル ユニヴァーシティー コレステロール誘発性ミトコンドリア機能不全を治療するための芳香族カチオン性ペプチドの使用
EP3060573B1 (en) 2013-10-23 2019-07-17 Kaneka Corporation Tetrapeptide compound and method for producing same
CA2932408A1 (en) 2013-12-02 2015-06-11 Stealth Biotherapeutics Corp Compositions and methods for treating vitiligo
JP6626446B2 (ja) 2013-12-27 2019-12-25 ステルス バイオセラピューティックス コープ 薬学的に適切な芳香族カチオン性ペプチド
EP2913287B1 (en) 2014-02-26 2018-01-03 Otis Elevator Company Governor for controlling the speed of a hoisted object relative to a guide member
HK1231493A1 (zh) 2014-03-03 2017-12-22 Stealth Biotherapeutics Corp 药学上相关的芳香族阳离子肽
WO2016004441A1 (en) 2014-07-03 2016-01-07 Stealth Peptides International, Inc. Methods for the prevention or treatment of acute myocardial infarction injury

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012521355A (ja) * 2009-03-20 2012-09-13 ザ ジェネラル ホスピタル コーポレイション ディー ビー エイ マサチューセッツ ジェネラル ホスピタル 熱傷及び二次性合併症の予防及び治療方法
JP2013501802A (ja) * 2009-08-12 2013-01-17 コーネル ユニヴァーシティー 代謝性症候群を予防し又は治療するための方法
JP2015507611A (ja) * 2011-12-09 2015-03-12 ステルス ペプチドズ インターナショナル インコーポレイテッド 芳香族カチオン性ペプチドおよびその使用
WO2015048647A1 (en) * 2013-09-30 2015-04-02 Cornell University Cardiolipin-targeted peptides inhibit beta-amyloid oligomer toxicity

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SHINOYAMA, M., ET AL.: ""Superior analgesic effect of H-Dmt-D-Arg-Phe-Lys-NH2 ([Dmt1]DALDA), multifunctional opioid peptide,", CHEM. BIOL. DRUG DES., vol. 80, no. 5, JPN6020050087, 2003, pages 771 - 774, ISSN: 0004604958 *

Also Published As

Publication number Publication date
AU2017249218B2 (en) 2020-08-27
US20190153032A1 (en) 2019-05-23
AU2020260489A1 (en) 2020-11-26
US10870678B2 (en) 2020-12-22
WO2017180535A1 (en) 2017-10-19
EP3442990A4 (en) 2019-12-18
CA3020393A1 (en) 2017-10-19
EP3442990A1 (en) 2019-02-20
US20200407395A1 (en) 2020-12-31
CN109563131A (zh) 2019-04-02
AU2017249218A1 (en) 2018-11-01

Similar Documents

Publication Publication Date Title
US10870678B2 (en) Chiral peptides
JP5841672B2 (ja) Ｎ−ベンジルアニリン誘導体及びその使用
JP2025010154A (ja) 線維症及び炎症の処置のための組成物
TW201117826A (en) Fatty acid niacin conjugates and their uses
KR102645633B1 (ko) 신경학적 장애를 치료하는 방법
CN109925312A (zh) 用于治疗眼病的组合物、制剂和方法
EP2552470B1 (en) Peptides for promoting angiogenesis and an use thereof
JP2021169519A (ja) 新規な細胞透過性サクシネート化合物
US12097179B2 (en) Carbazole derivatives for the treatment of fibrotic diseases and related symptoms, and conditions thereof
TW201240662A (en) Ester pro-drugs of [3-(1-(1H-imidazol-4-yl)ethyl)-2-methylphenyl] methanol for treating retinal diseases
JP2017526647A (ja) Ａｎｇ−（１−７）誘導体オリゴペプチド、ならびにそれを使用および作製するための方法
JP2025138792A (ja) 癌標的薬物ビヒクルとしてのリン脂質エーテルコンジュゲート
US7585846B2 (en) Compounds for delivering amino acids or peptides with antioxidant activity into mitochondria and use thereof
KR20250089568A (ko) 진통제 폴리펩티드
RS66246B1 (sr) Derivati para-hidrohinona kao vegf, tnf i/ili il inhibitori za lečenje neuroinflamtornih bolesti
WO2019006692A1 (zh) 用于治疗、改善或预防神经系统相关病症的化合物及其用途
JP2012530764A (ja) メキシレチンのアミノ酸およびペプチドプロドラッグ並びにその使用
US20060160748A1 (en) Compounds for delivering amino acids or peptides with antioxidant activity into mitochondria and use thereof
KR20150014910A (ko) 허혈-재관류계 질환의 치료 화합물
JP6987104B2 (ja) パ−キンソン病治療用の新規高透過薬物及びその組成物
US12194034B2 (en) Neutrophil exocytosis inhibitors
JP6596483B2 (ja) パ−キンソン病治療用の新規高透過薬物及びその組成物
JP2004168697A (ja) 網膜疾患治療剤
TW202425961A (zh) 一種κ阿片受體激動劑藥物組合物及其製備方法和用途
WO2020214518A1 (en) Methods of treating renal conditions using peptides that improve mitochondrial function

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200130

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200130

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20201203

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20201223

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210323

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210524

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20211001

A045 Written measure of dismissal of application [lapsed due to lack of payment]

Free format text: JAPANESE INTERMEDIATE CODE: A045

Effective date: 20220217